Crossmark

A systematic review and meta-analysis of randomized controlled trials: the effect of potassium-competitive acid blockers on nighttime symptoms of gastroesophageal reflux disease

Crossref DOI link: https://doi.org/10.1007/s10388-025-01181-0

Published Online: 2026-01-12

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Koo, Thai Hau

Fass, Ronnie https://orcid.org/0000-0002-4807-3052
License Information

Text and Data Mining valid from 2026-01-12

Version of Record valid from 2026-01-12
More Information

Article History

Received: 10 September 2025

Accepted: 23 December 2025

First Online: 12 January 2026

Declarations

:

: Ronnie Fass: Advisor – Takeda, Phathom Pharmaceuticals, GERDCare, Celexio, Dexcal, Carnot, Syneos, GIE Medical, BrainTree Labs/Sebela, Renexxion and Daewoong. Speaker: AstraZeneca, Takeda, Eisai Pharmaceuticals, Medicamenta, Carnot, Daewoong and Megalab. The remaining author did not have any conflict of interest to declare.

: Ethics approval was not required for this study.

: Patient consent was not required for this study.

Document is current

Any future updates will be listed below